Trials / Completed
CompletedNCT00109070
A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy used to treat metastatic colorectal cancer. This trial will enroll approximately 900 subjects with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin (bevacizumab) |
Timeline
- Start date
- 2000-09-01
- Completion
- 2003-04-01
- First posted
- 2005-04-25
- Last updated
- 2013-06-21
Source: ClinicalTrials.gov record NCT00109070. Inclusion in this directory is not an endorsement.